SCHEMBL4856192

SCHEMBL4856192

O=C1Nc2cc([N+](=O)[O-])ccc2Nc2cc(Cl)ccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
CHEK1 O14757 4/20 0.58
PDPK1 O15530 1/20 0.57
ROCK2 O75116 1/20 0.57
RPS6KA5 O75582 1/20 0.57
MAP4K4 O95819 1/20 0.57
CHEK2 O96017 1/20 0.57
CDK1 P06493 1/20 0.57
PIM1 P11309 1/20 0.57
RPS6KB1 P23443 1/20 0.57
CDK2 P24941 1/20 0.57
AKT2 P31751 1/20 0.57
MAPKAPK2 P49137 1/20 0.57
CDK8 P49336 1/20 0.57
GSK3A P49840 1/20 0.57
GSK3B P49841 1/20 0.57
CDK9 P50750 1/20 0.57
RPS6KA3 P51812 1/20 0.57
PRKX P51817 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31273494 0.81 KMT2A (0.83) MEN1KMT2ACHEK1PDPK1ROCK2
SCHEMBL193560 0.78 MEN1 (0.61) MEN1KMT2ACHEK1PDPK1ROCK2
SCHEMBL29242097 0.78 MEN1 (0.61) MEN1KMT2ACHEK1PDPK1ROCK2
SCHEMBL31344376 0.78 MEN1 (0.61) MEN1KMT2ACHEK1PDPK1ROCK2
SCHEMBL4858977 0.78 CHEK1 (0.51) MEN1KMT2ACHEK1PDPK1ROCK2
SCHEMBL29485956 0.77 CHEK1 (0.81) CHEK1ROCK2MAP4K4CHEK2CDK1
SCHEMBL4856816 0.77 CHEK1 (0.81) CHEK1ROCK2MAP4K4CHEK2CDK1
SCHEMBL4856162 0.77 CHEK1 (0.65) CHEK1PDPK1CDK8CES1TGM2
SCHEMBL4853307 0.77 CHEK1 (0.65) CHEK1PDPK1CDK8CES1TGM2
SCHEMBL4857611 0.77 CHEK1 (0.65) CHEK1ROCK2MAP4K4PIM1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1606268-B1 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS ABBVIE INC (US) 2015-05-20 EP disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed
US-20040254159-A1 Heterocyclic kinase inhibitors ABBOTT LABORATORIES 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254159-A1 Heterocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K1 MEN1 1677/4885KMT2A 1398/4885CHEK1 46/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 MEN1 2238/4885KMT2A 1376/4885CHEK1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.